You are here: Home » Markets » News
Business Standard

Morepen Laboratories rallies 17% in two days on fundraising plans

Morepen Laboratories board approved the issue of up to 5 crore equity shares to Liquid Holdings, an entity belonging to the promoter group of the company, at a price of Rs 38 per equity share

Morepen Laboratories Ltd | Buzzing stocks | Markets

SI Reporter  |  New Delhi 

market, markets, stock market, stock, stocks rise, stock rally

Shares of Morepen Laboratories extended their winning run to the second day in a row and jumped nearly 8 per cent to hit a fresh 52-week high on the BSE in Thursday's session after the company board approved raising Rs 433 crore via issuance of shares on a preferential basis.

So far in the two trading sessions, the scrip has gained 17 per cent. The stock of the smallcap pharma firm hit a fresh 52-week high of Rs 59.45 on the BSE today. At 10.55 am, it was trading 2.90 per cent higher at Rs 56.80 as against a decline of 0.31 per cent in the BSE Sensex at the same time.

The company on Wednesday said its board has approved raising over Rs 433 crore through the issue of shares to Switzerland's private venture capital firm Corinth Investment Holdings and Liquid Holdings, a promoter group of the company, on a preferential basis.

"The board of Directors considered and approved issue and allotment of up to 10.85 crore equity shares of the face value of Rs 2 each, on a preferential basis," it said in a regulatory filing.

Morepen Laboratories board approved the issue of up to 5 crore equity shares to Liquid Holdings, an entity belonging to the promoter group of the company, at a price of Rs 38 per equity share, for an aggregate amount of up to Rs 190 crore.

Furthermore, in a separate filing, the company said its board approved the investment proposed by Corinth Group, a global private investment Group headquartered in Switzerland, to the extent of $32.50 million (Rs 243 crore) in Morepen Laboratories out of a total $100 million investment in the promoter group.

Following the shareholder and regulatory approval, Corinth would be allotted 5.85 crore new equity shares on a preferential basis. This shareholding would equate to a 9.41 per cent equity stake in the company on a fully expanded capital base. The balance $67.50 million would be in the promoter group companies, it said.

The board of directors has also approved an allotment of 5 crore fresh equity shares to the promoter group in lieu of the 9.85 crore unsubscribed warrants issued in the last financial year which lapsed due to technical reasons.

The company said total fund infusion in Morepen Laboratories, including investor funds and promoter's equity, will be Rs 565 crore.

The funds would be used in the expansion or scaling up of the company's R&D centre/facilities to meet the significantly enhanced active pharmaceutical ingredient (API) demand.

It will also be utilised for setting up a new API plant to meet the significant ramp-up in scale and pipeline the company is working on. The firm will also use the funds, among other purposes, to establish a facility for finished dosages as per USFDA standards at Morepen's pharma complex in Baddi, Himachal Pradesh to cater to highly sophisticated/regulated such as the US and Japan.

Besides, the company would also invest in world-class diagnostics facilities including the manufacture of critical inputs, components and enzymes to meet regulated market standards. It would use the funds to add to the new products and brands under the Dr Morepen umbrella and investment in new-age personal care and skincare brands.

An Extraordinary General Meeting (EGM) of the company will be held on May 20, 2021, to seek the approval of the members for the said preferential issue.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, April 29 2021. 11:26 IST